Following the rerating, Danaher shares seem to have found their footing, with downward [earnings] estimate revisions ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” fourth quarter 2024 investor letter ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

Fintel reports that on March 14, 2025, Stifel upgraded their outlook for Danaher (NYSE:DHR) from Hold to Buy. Analyst Price ...

Shares of Danaher Corp. DHR slid 1.28% to $212.07 Friday, on what proved to be an all-around positive trading session for the ...

Veralto delivers solid growth but at demanding multiples. Find out why VLTO stock is still too rich for a 'buy' despite a ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

As layoffs continue to strike biopharma outfits big and small, life sciences technology and service provider Cytiva is ...

AbbVie, Danaher, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock ...

AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

The company clarified that the remainder of the Westborough facility will remain open. Cytiva was previously GE Healthcare Life Sciences before its $21.4B acquisition by Danaher Corp. Now as a ...

Shares of Danaher Corp. DHR slipped 3.23% to $205.23 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.70% to 5,614.56 and Dow ...